Possible Risk Factors Associated with Tuberculosis Treatment Failure Among Patients Attending Tuberculosis Treatment Centers in Kano State, Nigeria

Fatihu A. R., Binta M. A., Nabila A. A.

Abstract


The widespread failure of tuberculosis chemotherapy has led to an increase in mortality and morbidity associated with tuberculosis infection. This study was aimed at assessing the possible risk factors associated with tuberculosis treatment failure in patients attending Aminu Kano Teaching Hospital (AKTH) and Infectious Disease Hospital (IDH), Kano State. Treatment outcomes of the 436 tuberculosis patients attending selected hospitals in 2018 were obtained using a retrospective study (review of the medical record). In 2019 consented subjects on TB treatment from the hospital (187 from AKTH and 213 from IDH) were randomly selected and followed up for 5 months to assess the cure and treatment failure rate. A structural questionnaire was employed to document clinical information, sociodemographic data, and other pertinent details. Tuberculosis-positive patients were confirmed by microscopic examination of sputum using Ziehl–Neelsen staining techniques. Subjects with Acid Fast Bacilli positive sputum after 5 months with or without clinical symptoms were considered to have treatment failure. The tuberculosis and drug resistance status of the subjects were confirmed using the GeneXpert System. Of the total number of 400 subjects enrolled (78.5%) had adequate treatment response and (21.51%) had treatment failure based on retrospective and prospective information. Up to (65.1%) of subjects with treatment failure were found to be Rifampicin sensitive and (34.9) were Rifampicin resistant p>0.05. Tuberculosis treatment failure rate was found to be significantly different between widows (53.8%), students (36.0%), primary level of education (73.5%), and between tuberculosis subjects with HIV (28.2%) when compared to subjects with tuberculosis only (p<0.05). Tuberculosis treatment failure was also found to be more common among males (23.9%) than females (19.33%), age group (0-9) years (75.0%), and among subjects with diabetes mellitus (30%), cigarette smokers (22.7%), those taking care by their families (30%) and poor adherence to treatment (47.4%) p>0.05. This study revealed that some factors such as marital status, occupation, western educational level, and HIV status, can predispose individuals to fail treatment and consequently increase the risk of developing drug resistance in a population. Therefore, special attention should be given to this high-risk group during TB treatment in the study area.



Keywords


Chemotheraphy, Tuberculosis, Mortality, Morbidity, Retrospective study, Rifampicin.

Full Text:

PDF

References


Tukur AD, Aminu AI, Sale AK, Olabamiji JO, Aliyu UA, Bashir AM et al. The Role of MTBDR plus ver 2.0 in the Detection of Drug resistant tuberculosis in smear negative pulmonary tuberculosis in Kano, Nigeria, Nigerian. J Microbiol. 2019;33(2):4397–402.

Chaudhary J, Chhina D, Malhotra P, Gupta R. Role of line probe Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Drug Resistance directly from Clinical Samples. Natl J Lab Med. 2018;7(1):3249–54.

World Health Organization, Global Tuberculosis Programme. Global Tuberculosis Report 2015. Geneva: World Health Organization; 2015.

Gerald L, Mandell JE, Bennett R. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone/Elsevier; 2012. p. 250.

Southwick FS. Chapter 4: Pulmonary infections. In: Southwick FS, editors. Infectious Diseases: A Clinical Short Course. 2nd edition. New York: McGraw-Hill Medical; 2008.

Jindal SK. Textbook of pulmonary and critical care medicine. New Delhi: Jaypee Brothers Medical Publishers; 2011. p. 525.

Federal Ministry of Health. National Tuberculosis, Leprosy and Buruli Ulcer Management and Control Guidelines. 6th edition. Abuja: Federal Ministry of Health; 2015.

World Health Organization, Global Tuberculosis Programme. Global Tuberculosis Report, 2019. Geneva: World Health Organization; 2019.

World Health Organization. (2019). Tuberculosis. [online] Who.int. Available from: https://www.who.int/health-topics/tuberculosis#tab=tab_1

Imam TS, Oyeyi TI. A Retrospective study of pulmonary tuberculosis (PTB) prevalence amongst patients attending infectious disease hospital (IDH) in Kano, Nigeria Bayero. J Pure Appl Sci. 2008;1:10–5.

Ameh J, Shuaibu UA, Aminu I, Henry M, Humphrey M, Kingsley O, et al. Improving the Case Detection of Pulmonary tuberculosis by bleach microscopy method in the North West of Nigeria. J Med Lab Diagnosis. 2013;4(3):34–7.

National TB and Leprosy Control Programme (NTBLCP). Government of Nigeria, Abuja, Nigeria; 2014.

World Health Organization. Global Tuberculosis Report 2015. Geneva: World Health Organization; 2015.

Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug-resistant tuberculosis? A systematic review. PLOS ONE. 2009;4(5):e5561. doi: 10.1371/journal.pone.0005561.

World Health Organization, Global Tuberculosis Programme. Global tuberculosis control: WHO report 2010. Geneva: World Health Organization; 2010.

Jibrin YB, Ali AB, Saad ST, Kolo PM. Prevalence of Treatment Failure among Pulmonary Tuberculosis Patients in Federal Medical Centre, Gombe, Northeastern Nigeria. ISRN Infect Dis. 2013;2013:1–4. doi: 10.5402/2013/461704.

Karen IB, Willian MK, Nicholas JW. Antimalarial dosing regimens and drug resistance. Rev. Cell Press. 2008;3(240):127–134.

Davies PD, Gordon O, Davies GR. Clinical Tuberculosis. 5th edition. Boca Raton: CRC Press; 2007.

Rothel JS, Andersen P. Diagnosis of latent mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? Expert Rev Anti Infect Ther. 2005;3(6):981–93. doi: 10.1586/14787210.3.6.981.

Salami AK, Oluboyo PO. Management outcome of pulmonary tuberculosis: a nine-year review in Ilorin. West Afr J Med. 2003;22(2):114–9. doi: 10.4314/wajm.v22i2.27928.

FitzGerald JM, Wang L, Elwood RK. Tuberculosis: 13. Control of the disease among Aboriginal people in Canada. CMAJ Can Med Assoc J. 2000;162(3):351–5.

Hasker E, Khodjikhanov M, Usarova S, Asamidinov U, Yuldashova U, van der Werf MJ, et al. Default from tuberculosis treatment in Tashkent, Uzbekistan; who are these defaulters and why do they default? BMC Infect Dis. 2008;8:97. doi: 10.1186/1471-2334-8-97.

Namukwaya E, Nakwagala FN, Mulekya F, Mayanja-Kizza H, Mugerwa R. Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda. Afr Health Sci. 2011;11;Suppl 1:S105–11. doi: 10.4314/ahs.v11i3.70079.

Arora VK. Trends of extra-pulmonary tuberculosis under revised national tuberculosis control programmed: a study from south Delhi. Indian J Tuberc. 2006;53:77–83.

Pennap GR, Giyan JN, Eleboda AT. Prevalence of pulmonary tuberculosis (PTB) among people living with HIV/AIDS (PLWHA) in Keffi and its environs. Indian J Microbiol. 2009;49(3):233–6. doi: 10.1007/s12088-009-0035-8.

Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sinha S. Comparative evaluation of genotype MTBDRplus line probe Assay with solid culture method in early diagnosis of multidrug-resistant tuberculosis at a Tertiary Care Centre in India. PLOS ONE. 2013;8(9):1371–42.

El-Shabrawy M, El-Shafei DA. Evaluation of treatment failure outcome and its predictors among pulmonary tuberculosis patients in Sharkia Governorate, 2013–2014. Egypt J Chest Dis Tuberc. 2017;66(1):145–52. doi: 10.1016/j.ejcdt.2015.11.002.

Eltringham IJ, Drobniewski F. Multiple drug-resistant tuberculosis: aetiology, diagnosis, and outcome. British Medical Bulletin. 1998;54(3):569–78. doi: 10.1093/oxfordjournals.bmb.a011711.

Golden MP, Vikram HR. Extrapulmonary tuberculosis: overview. American Family Physician. 2005;72(9):1761–8.

Helen AOA, V, Afia FAM. Patient-related factors affecting adherence to antimicrobial medication in an urban estate in Ghana. Malar Res Treat. 2015;2015:1–9.




DOI: https://doi.org/10.37591/rrjomv.v13i2.3263

Refbacks

  • There are currently no refbacks.